Renovare Fuels is developing technology that turns biodegradable waste from homes and industry into petrol or diesel fuel.

Renovare Fuels completed its SyndicateRoom round in February 2017, overfunding to £658,337.

The story

Renovare Fuels has developed patented technology that allows industrial or household waste to be converted into liquid diesel and petrol, with the goal of fuelling everyday vehicles without the need for any engine modifications. The technology was developed in conjunction with NASA and the US Department of Energy.

Where current fuel production from biodegradable waste uses only a fraction of the gas produced from this process, Renovare Fuels’ new method uses up to 100% of the available gas – including CO2 – to generate the fuel, making it more efficient and potentially profitable.

With the widely publicised reduction of government subsidies for waste-to-energy plants in 2017, Renovare believes that this technology will help plants to become more efficient and self-sustainable and allow landfill operators to resell the fuel or use it for their own refuse collection vehicles.

Since leaving the army after ten years of service in the Royal Engineers and UK Special Forces, CEO Kevin Godlington has founded several charities and a number of successful environmentally and socially responsible companies, overseeing them from startup to exit. Chairman Matthew Stone is an active investor in the clean-technology space and has an established research catchment exceeding $6bn annually.

The company plans to use raised funds to construct and run a commercial-scale mobile demonstration unit to provide initial proof of concept to potential new partners in the UK.

The lead investor

Lead investor Robert Lawrence invested £50,000 into Renovare Fuels. Joining the army in 1977, Robert was awarded the Military Cross for his actions leading the final assault on Mt. Tumbledown during the final stages of the Falklands War in 1982. He has extensive experience in international multimedia organisations and private military companies.

Robert is a successful entrepreneur, and an investor in socially and environmentally conscious companies. Robert has history of investing in property, including a successful and ongoing investment in an Asian property fund. He has also made investments into the alternative energy sector.

Robert explains why he invested in Renovare Fuels:

‘The opportunity to be involved in a ‘green’, new technology company with a management team which I believe in. The capacity to store and transport a product that can be used in conventional engines with no need for adaption.’

See current opportunities

Adoreboard Limited

EIS
Software & Computer Services
Adoreboard’s proprietary software allows companies to turn customer emotions into actionable insights. Lead investor, Michael Black, MBE, is currently serving as Chairman and Non-Executive Director for a number of companies, including Adoreboard.

Active

Trading status

£9,703

Average investment

£261,985

Total raised

Squirrel Financial Wellbeing

EIS
Financial Services
Squirrel aims to make it easy and intuitive to create – and stick to – a budget. Find out about Squirrel's funding round and lead investor Jos Evans here.

Active

Trading status

£6,852

Average investment

£465,929

Total raised

Orthogem

EIS
Medtech
Orthogem is focused on the discovery and development of advanced synthetic bone graft. Find out more about Orthogem's raise here.

Active

Trading status

£10,112

Average investment

£566,284

Total raised

Cipher Surgical

EIS
Medtech
Cipher Surgical offers an innovative method of maintaining vision during a laparoscopic procedure. Read about Cipher Surgical's crowdfunding campaigns here.

Active

Trading status

£7,192

Average investment

£1,014,150

Total raised

Aeristech Limited

EIS
Engineering & Manufacturing
Aeristech successfully funded twice on SyndicateRoom. They manufacture patented electric superchargers: reducing fuel consumption and CO2 emissions.

Active

Trading status

£9,128

Average investment

£483,766

Total raised

Small Pharma Ltd

EIS
Pharmaceuticals & Biotechnology
Small Pharma is developing an oral rapid-acting antidepressant they believe could make a difference in the lives of those experiencing severe depression.

Active

Trading status

£11,699

Average investment

£783,849

Total raised